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Abstract Fibroblast growth factor-2 (FGF-2) is mitogenic for
the human breast cancer cell line MCF-7; here we investigate
some of the signaling pathways subserving this activity. FGF-2
stimulation of MCF-7 cells resulted in a global increase of
intracellular tyrosine phosphorylation of proteins, particularly
FGF receptor substrate-2, the protooncogene product Src and
the mitogen-activated protein kinase (MAP kinase) cascade. A
major increase in the tyrosine phosphorylation of a 30-kDa
protein species was also found. This protein was identified as
cyclin D2 by mass spectrometry after trypsin digestion.
Immunoprecipitation of cyclin D2 and immunoblotting with
anti-phosphotyrosine antibodies confirmed that the tyrosine
phosphorylation of cyclin D2 was indeed induced by FGF-2
stimulation. In addition, pharmacological inhibition of Src (with
herbimycin A and PP2), and of the MAP kinase cascade (with
PD98059), confirmed that Src activity is required for the FGF-2-
induced phosphorylation of cyclin D2 whereas MAP kinase
activity is not. Thus, tyrosine phosphorylation of cyclin D2 may
be a key regulatory target for FGF-2 signaling. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Fibroblast growth factor-2 (FGF-2), the most studied mem-
ber of the FGF family of growth factors, has been isolated
from a large variety of tissues and various e¡ects of this mol-
ecule have been reported for the control of cellular growth,
di¡erentiation and migration [1]. FGF-2 activates its target
cells by binding to speci¢c tyrosine kinase receptors (FGFRs)
on the cell surface, which immediately induces transient phos-
phorylation on their tyrosine residues [2]. The activated
FGFR further associates with, and phosphorylates a set of
cytoplasmic signaling molecules containing SH2 domains,
which in turn activate several pathways, and in particular
the mitogen-activated protein kinase (MAP kinase) cascade.
The MAP kinase pathway ultimately leads to the regulation
of gene expression essential for proliferation [3]. However, a
variety of signaling pathways has been described in the diverse
cellular systems used to study FGF intracellular signaling, and
a complete model for one de¢ned cell type has yet to be
established.
The role of FGFs in tumor progression includes the stim-
ulation of cancer cell growth and metastasis as well as angio-
genesis [1,4]. In breast cancer, the overexpression of FGF
family members as well as FGFRs has been reported in a
signi¢cant percentage of breast tumors [5^10]. Moreover,
high levels of FGF have been detected in sera from patients
with breast cancer [11]. We and others have found that FGF-2
is a strong mitogen for the prototypic MCF-7 breast cancer
cell line [12^14] and that this activity involves a recruitment of
G0 cells into the cell cycle, as well as a shortening of the G1
phase [15]. Under other experimental conditions, FGF-2 has
been shown to inhibit breast cancer cell growth [16,17], under-
lining the pleiotrophic activities of this growth factor. How-
ever, the transfection of MCF-7 cells by FGFs induces a pro-
gression towards an aggressive and metastatic phenotype,
supporting a role for autocrine and paracrine involvement
of FGFs during malignant progression [18,19]. Interestingly,
Liu et al. (1999) have shown that functional Rac-1 and Nck
are required for FGF-2-induced proliferation in MCF-7 cells
[20]. However, to date, the intracellular signaling pathways for
the FGF-2 stimulation of breast cancer cells remain largely
unknown.
In the present study, we have explored the signaling path-
ways involved in the mitogenic e¡ect of FGF-2 in MCF-7
cells. Our results show that FGF-2 induces the activation of
FGFR, FRS2, Src and the MAP kinase. Moreover, pharma-
cological inhibition indicated that the activation of both Src
and the MAP kinase cascade is required for FGF-2 mitoge-
nicity. Interestingly, a strong increase in the tyrosine phos-
phorylation of a 30-kDa protein was found to be induced
by FGF-2; this protein was identi¢ed as cyclin D2 by mass
spectrometry. The induction of tyrosine phosphorylation of
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cyclin D2 by FGF-2 stimulation was further con¢rmed using
speci¢c antibodies.
2. Materials and methods
2.1. Materials
FGF-2 was from Amersham (France). The pharmacological inhib-
itors PD98059, K252-a, herbimycin A and PP2 were from Calbiochem
(France) and genistein was from Sigma (France). All the cell culture
products were from Bio-Whittaker (Belgium) except insulin (Organon,
France), ¢bronectin (Falcon-Biocoat, France) and transferrin (Sigma,
France). The petri dishes were purchased from Greiner (Fisher,
France). The antibodies against phosphotyrosine (PY99), FRS2,
ERK-1, and cyclin D2 were purchased from Santa Cruz Biotechnol-
ogy (Tebu, France). The rabbit polyclonal anti-FGFR (nominally
against R1) was from UBI (Euromedex, France). Trypsin was pur-
chased from Promega (France).
2.2. Cell culture
MCF-7 human breast cancer epithelial cells were obtained from the
American Type Culture Collection. They were cultured between pas-
sages 15^25 in minimal essential medium (Earle’s salts) supplemented
with 20 mM HEPES, 2 g/l sodium bicarbonate, 10% fetal calf serum
(FCS), 1% non-essential amino acids, 2 mM L-glutamine, 5 Wg/ml
insulin, 40 U/ml penicillin^streptomycin, 50 Wg/ml gentamicin. Cells
were grown at 37‡C in a humidi¢ed atmosphere of 5% CO2.
2.3. Cell growth assay
MCF-7 cells were seeded at 30 000 cells/ml in 35-mm dishes in
complete medium. When 40% con£uence was reached, cells were
washed twice and starved in a serum-free medium containing ¢bro-
nectin (2 Wg/ml) and transferrin (30 Wg/ml) for 24 h. Cells were then
treated for 48 h with FGF-2 (10 ng/ml) in fresh serum-free medium in
the presence of various inhibitors at di¡erent concentrations: 1^100
WM genistein, 5 nM K-252a, 1^100 WM PD98059, 25^100 nM herbi-
mycin A, 5^15 nM PP2. After 48 h of treatment, cell numbers were
determined after trypsinization of the monolayer culture with 0.25%
trypsin/EDTA solution. In parallel with the experiments with FGF-2,
MCF-7 cells were treated with the same inhibitors in control serum-
free medium to ensure that the e¡ect of each compound on FGF-2-
induced proliferation was not due to a non-speci¢c toxicity.
2.4. Cell lysate preparation
Cells were seeded in 100-mm dishes at 500 000 cells per dish. They
were grown to pre-con£uency and then made quiescent in serum-free
MEM for 24 h. Pretreatment of cells by 10 WM pervanadate before
addition of FGF-2 was performed for 10 min. FGF-2 was then di-
rectly added to the medium (10 ng/ml) for another 10 min. When
inhibitors were used, they were added directly into the medium at
the required concentration 50 min before pretreatment with pervana-
date. Cells were rinsed with cold PBS containing 100 WM orthovana-
date. Cell lysates were prepared by adding 200 Wl of immunoprecipi-
tation (IP) lysis bu¡er (150 mM NaCl, 50 mM Tris pH 7.5, 1%
Nonidet P-40, 0.1% SDS, supplemented with the following inhibitors:
orthovanadate, PMSF, and Na4P2O7 at 1 mM, leupeptin and apro-
tinin at 10 Wg/ml, pepstatin at 1 Wg/ml) to each dish, kept 15 min on
ice, transferred to 1.5 ml Eppendorf tubes, boiled for 10 min, and
centrifuged for 2 min at 10 000Ug. The supernatants were stored at
380‡C. Protein content in cell lysates was measured with the Bio-Rad
protein assay.
2.5. Immunoprecipitation and Western blot analysis
Immunoprecipitations were performed by incubation of cell lysates
(500 Wg protein) at 4‡C for 2 h with the appropriate antibody, fol-
lowed by incubation of the immunocomplexes with protein A-agarose
10% (Sigma) beads for 1 h at 4‡C. The beads were then washed three
times with the IP bu¡er. The immunocomplexes were resuspended in
Laemmli sample bu¡er, boiled for 5 min and subjected to 10% SDS^
PAGE. Proteins were transferred onto nitrocellulose membrane
(Schleicher and Schuell). The membranes were immersed for 2 h at
room temperature in blocking bu¡er: Tris-bu¡ered saline, 0.1%
Tween-20 containing 5% non-fat dry milk (for detection of FGFR,
ERK, and cyclin D2), 1% non-fat dry milk (for detection of FRS2) or
3% BSA (for detection of phosphotyrosine), and were then incubated
overnight at 4‡C with the appropriate antibody. The membranes were
then incubated with the appropriate secondary antibody for 1^2 h
and, after extensive washing, antibody complexes were detected by
the enhanced chemoluminescence (ECL) Western blotting detection
system according to the manufacturer’s instructions (Amersham).
2.6. Src kinase assay
Src kinase activity was determined by immunoprecipitation with the
anti-Src monoclonal antibody 327 [21]. The antibody complexes were
washed 3 times with lysis bu¡er and once with kinase bu¡er (30 mM
Tris pH 7.4, 10 mM MnCl2), and were subsequently incubated in 50
Wl of kinase bu¡er containing 10 WCi of (Q-32P)-ATP and 2 Wg acid-
denatured enolase (Sigma) at room temperature for 10 min. The phos-
phorylated proteins were resolved by 7.5% SDS^PAGE, transferred to
nitrocellulose, visualized by autoradiography and bands quantitated
using NIH Image software. Subsequently, immunoblot analysis was
performed using the anti-Src-2 antibody [21] and quantitated by £uor-
imaging (Molecular Dynamics) with the ECL+reagent (Amersham
Pharmacia) procedure. The results of at least six separate experiments
were averaged and the standard deviation calculated.
2.7. Mass spectrometry analysis
Protein identi¢cation was performed as described [22,23] with mod-
i¢cations. Silver nitrate-stained proteins were cut out from the gel and
washed three times with 400 Wl of a 125 mM ammonium carbonate/
acetonitrile (ACN) 1:1 (v/v) solution for 20 min with shaking. The
wash solution was discarded and the pieces of gel were dried at room
temperature for 2 h. Enzymatic cleavage was initiated by re-swelling
the gel in ammonium carbonate solution (125 mM); 50 mM acetic
acid was then added, and ¢nally the digestion was initiated by adding
50 mM acetic acid containing 7^7.5 units of trypsin (Promega). After
absorption of the protease solution, aliquots (5 Wl) of pure water were
added sequentially. The gel slices were placed in an Eppendorf tube
and a minimum volume of water was added to totally immerse the gel
pieces. The digestion was carried for 12^16 h at 37‡C. The liquid was
collected and the resulting peptides recovered after two extractions
with a solution containing 45% acetonitrile and 10% formic acid.
To recover very hydrophobic peptides, a third extraction with 95%
acetonitrile, 5% formic acid was performed. The total extract was then
dried using a Speed Vac-concentrator (Savant).
MALDI-TOF analysis of trypsin digests was performed on a Vision
2000 (Finnigan, Bremen, Germany) re£ector instrument in positive
ion mode at an accelerating voltage of 6 kV. Peptides were resus-
pended in CH3CN/H2O (1:1) containing 0.5% formic acid of which
0.5 Wl were mixed directly onto the target with 1 Wl of 2,5-dihydroxy
benzoic acid matrix solution (10 mg/ml in CH3OH/H2O, 7:3). Be-
tween 30 and 50 laser shots were accumulated to obtain the ¢nal
spectrum. Mass measurements were then ¢nalized after peak smooth-
ing and internal calibration using the monoisotopic mass of the two
autolysis trypsin fragment and DHB matrix ions respectively at
2211.1, 842.8 and 273.04, resulting in mass accuracy better than 0.2
Da. Protein database searching was performed using MS-Fit (http://
prospector.ucsf.edu/htmlucsf3.0/ms¢t.htm) according to the average
molecular weight of [M+H] peptide ions.
3. Results
3.1. Pharmacological inhibition of FGF-2 mitogenic e¡ect
MCF-7 cells were treated with each inhibitor in the pres-
ence of FGF-2, and the cell number measured after 2 days of
treatment. For each inhibitor used we determined the dose^
response for the inhibition of FGF-2 mitogenic activity (data
not shown). Genistein inhibited the proliferation induced by
FGF-2 (Fig. 1), con¢rming that FGF-2 stimulates cell growth
through tyrosine kinase pathways. In contrast, a speci¢c in-
hibitor of the NGF receptor (TrkA) tyrosine kinase, K-252a,
which inhibits NGF-induced proliferation in MCF-7 cells [24],
had no e¡ect on FGF-2-induced proliferation (Fig. 1). Herbi-
mycin A and PP2 are known to inhibit Src and Src-related
kinases by binding to their SH2 domains. These two inhibitors
markedly decreased the mitogenic activity of FGF-2 (Fig. 1),
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suggesting that Src kinase activity is involved in the signaling
of this growth factor. In contrast, the PI3 kinase inhibitor
wortmannin (5^15 nM) had only a slight inhibitory e¡ect on
the mitogenic activity of FGF-2, even when the medium was
changed after 24 h of treatment (data not shown). This indi-
cates that PI3 kinase is probably not crucial for the mitogen-
esis induced by FGF-2 in breast cancer cells. MAP kinase
pathway involvement in the FGF-2 mitogenic e¡ect in
MCF-7 cells was investigated using the synthetic MEK-1 in-
hibitor, PD98059. At a concentration of 10 WM, the mitogenic
e¡ect of FGF-2 was completely inhibited (Fig. 1), demonstrat-
ing that MAP kinase activity is necessary for the mitogenic
stimulation of MCF-7 cells by FGF-2.
3.2. Tyrosine phosphorylation induced by FGF-2
The tyrosine phosphorylation induced by FGF-2 in MCF-7
cells was studied after immunoprecipitation and Western blot-
ting of cell lysates using an anti-phosphotyrosine antibody.
Several bands with apparent molecular weights of 110, 95,
90, 85^70, 64, 60, 45 and 30 kDa were found phosphorylated
after 10 min of stimulation with FGF-2 (Fig. 2). The 45-kDa
protein has a molecular weight corresponding to the ERK-1/2
isoforms known to be regulated by growth factors; the 60^
64-kDa band could correspond to ERK-4 and/or Src, which
have a molecular mass of about 60 kDa and are also reported
to be phosphorylated by MEK in response to growth stimuli
[3].
3.3. FGFR, FRS2, Src and MAP kinase activation
We used a polyclonal antibody to immunoprecipitate
FGFR-1, and its activation was detected by immunoblotting
with anti-phosphotyrosine antibodies. Tyrosine phosphoryla-
tion of the FGFRs was observed after 10 min of stimulation
by FGF-2 (Fig. 3A). Di¡erences observed in FGFR phos-
phorylation were not due to di¡erences in protein quantity,
as we reprobed the membrane with the anti-FGFR antibody.
Similarly, FGF-2 induced the tyrosine phosphorylation of the
FGF receptor substrate FRS2, a membrane-anchored docking
protein involved in the activation of the Ras/MAP kinase
cascade through FGFR (Fig. 3B).
As we have shown an inhibition of FGF-2-induced prolif-
eration by herbimycin A and PP2, we further studied Src
Fig. 1. Pharmacological inhibition of FGF-2 mitogenic activity on
MCF-7 cells. Quiescent MCF-7 cells were stimulated with FGF-2
(10 ng/ml) for 48 h with or without inhibitors (genistein 10 WM, K-
252a 5 nM, PD98059 10 WM, herbimycin A 25 nM, PP2 15 nM)
and the cell number determined. For each inhibitor, a dose^response
curve was generated and only the e¡ect for the optimal concentra-
tion is presented here. Results represent the average of triplicate de-
terminations for two independent experiments.
Fig. 2. FGF-2-induced tyrosine phosphorylation. Cells were stimu-
lated with 10 ng/ml of FGF-2 in serum-free medium for 10 min as
described in Section 2. Cell lysates were immunoprecipitated with
anti-phosphotyrosine antibodies and subjected to immunoblot analy-
sis with the same antibody. Molecular weight is indicated in kDa.
The arrow indicates the position of the 30-kDa band which has
been subjected to analysis by mass spectrometry.
Fig. 3. Activation of FGFR, FRS2, and MAP kinase. Cells were ex-
posed to 10 ng/ml of FGF-2 for 10 min. Cell lysates were prepared
as described in Section 2 and immunoprecipitated with anti-FGFR
(A) or anti-FRS2 antibodies (B). The immunocomplex was resolved
by SDS^PAGE and immunoblotted with anti-phosphotyrosine anti-
bodies. C: MAP kinase activation. Cells were stimulated for the in-
dicated times with FGF-2 at 10 ng/ml. Lysates were immunoprecipi-
tated with anti-ERK1 antibodies and immunoblotted with anti-
phosphotyrosine or anti-ERK1 antibodies.
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activation. Because the Src protein can be phosphorylated on
tyrosine in an inactive, as well as an active state [25], we used
an in vitro kinase assay in the manner of LaVallee and co-
workers [21] to determine the e¡ects of FGF-2 on Src activity.
The activity of Src was not stimulated by 5 ng/ml FGF-2 in
the MCF-7 cells, but was markedly stimulated by 10 ng/ml; at
50 ng/ml it was already starting to be inhibited (Fig. 4). Max-
imal activity for the FGF-2 was reached within 10 min,
whereafter it declined. Quantitative £uorimaging results using
the ECL+visualizing reagent demonstrated that although
there were changes in Src activities brought about by FGF-
2, there were no major changes in the general Src pool at any
of the times or concentrations tested (data not shown).
To visualize MAP kinase activation, extracts of MCF-7
cells were immunoprecipitated with an ERK1-speci¢c anti-
body and immunoblotted for phosphotyrosine. MAP kinases
(p42, p44) were slightly phosphorylated in control, unstimu-
lated cells, whereas treatment with FGF-2 resulted in a rapid
and transitory activation of MAP kinase (Fig. 3C). To dem-
onstrate equal loading of proteins, the blot was stripped and
reprobed with a MAP kinase antibody, which recognized both
the phosphorylated and non-phosphorylated forms. The use
of speci¢c ERK2 antibodies showed the same result, although
the signal was less strong (data not shown).
3.4. Detection of cyclin D2 tyrosine phosphorylation induced by
FGF-2
As shown in Fig. 2, there was a major increase in the tyro-
sine phosphorylation of a 30-kDa protein induced by FGF-2
stimulation. None of the antibodies that we used recognized
this 30-kDa protein. Consequently, we used mass spectrome-
try to identify this protein. The band corresponding to the 30-
kDa protein was cut out and submitted to in-gel trypsin di-
gestion. MALDI-TOF analysis revealed a spectrum of tryptic
peptides (Fig. 5). This allowed the identi¢cation of the 30-kDa
protein as the cyclin D2, with 4/6 matched tryptic peptides
covering 10% of the protein sequence (Table 1). MALDI-TOF
mass spectrometry is a powerful method for characterization
of proteins after database searching [22,23,26]. However, this
method does not monitor the entire population of peptides
resulting from the tryptic digestion of a protein. This results
from di¡erences in the charge and mass of the ion species
generated after trypsin digestion, which leads to the preferen-
tial protonation of the low mass, and more basic peptides. It
should be emphasized that only small or basic peptides can be
detected in MALDI-TOF. Thus, the identi¢cation of a protein
is based on the ¢ngerprint of the molecule obtained after
trypsin digestion, and not on the characterization of the entire
molecule. Di¡erences in amino acid sequence between the
di¡erent categories of cyclin D (1, 2 or 3) are important
and the fragments that we have obtained speci¢c identify
the D2 form. In particular, we have observed a tryptic frag-
ment of 1667.90 Da corresponding to the N-terminal end of
cyclin D2, which does not exist in cyclins D1 and D3. The
tyrosine phosphorylation of cyclin D2 by FGF-2 was further
Fig. 5. MALDI-TOF peptide mass ¢ngerprint spectrum of the 30-
kDa phosphotyrosyl protein regulated by FGF-2. The band corre-
sponding to the 30-kDa phosphotyrosyl protein that we found regu-
lated by FGF-2 (indicated by an arrow in Fig. 2) was cut out from
a silver-stained gel of anti-phosphotyrosine immunoprecipitated ma-
terial and submitted to trypsin digestion and MALDI-TOF mass
spectrometry as described.
Table 1
Peptide mass ¢ngerprint of the 30-kDa phosphotyrosyl protein
Masses
submitted
MH
matched
Delta
Da
Start amino
acid
End amino
acid
Peptide sequence consistent with mass Modi¢cations
1636.00 1636.8157 0.2157 180 193 (K)HAQTFIALCATDFK(F) ^
1667.90 1667.8362 0.0638 1 13 (-)MELLCHEVDPVRR(A) ^
1924.10 1923.9131 0.1869 57 71 (R)RMVATWMLEVCEEQK(C) ^
1955.70 1955.9029 30.2029 57 71 (R)RMVATWMLEVCEEQK(C) 2 Met-ox
Tryptic fragment masses obtained by MALDI-TOF analysis (Fig. 5) are listed. The amino acid sequences shown are deduced from the trypsin
fragments after database searching. Abbreviations: Met-ox: oxidated methionine.
Fig. 4. Quantitation of Src kinase activity. MCF-7 cells were ex-
posed to di¡erent concentrations (0, 5, 10, 50 ng/ml) of FGF-2 and
for 0, 10 or 30 min with 10 ng/ml FGF-2. Src kinase activity was
determined by immunoprecipitation with the anti-Src monoclonal
antibody 327 and in vitro kinase assays performed using enolase as
a substrate. The density of the enolase bands was then quantitated
using calibrated densitometry. Representative enolase bands appear
above the graph. Each bar represents the mean+S.D. of six replicate
cell preparations.
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con¢rmed using speci¢c antibodies. As shown in Fig. 6A,
when we performed immunoprecipitation with either anti-
phosphotyrosine or anti-cyclin D2 antibodies, followed by
immunoblotting for cyclin D2, we detected the same band
at 30 kDa. In addition, immunoprecipitation of cyclin D2
followed by immunoblotting with anti-phosphotyrosine anti-
bodies con¢rmed that tyrosine phosphorylation of cyclin D2
is induced by FGF-2 and that this phosphorylation is inhib-
ited by PP2 but not by PD98059 (Fig. 6B).
4. Discussion
In this study, we have examined the intracellular signaling
pathway involved in the FGF-2 mitogenic stimulation of the
breast cancer cell line MCF-7. Immunoblot analysis of phos-
photyrosyl proteins from MCF-7 cells revealed changes in the
tyrosine phosphorylation of several bands. Speci¢cally, FGF-
2 induced an increase in the activation of FGFR, FRS2, Src
and MAP kinase. We further detected a 30-kDa protein
whose tyrosine phosphorylation was induced by FGF-2; this
we identi¢ed with mass spectrometry and immunoblotting as
cyclin D2.
The FGFR complement was rapidly tyrosine phosphorylat-
ed after FGF-2 stimulation of MCF-7 cells. To date, four
distinct members of the FGFR family have been described
(£g or FGFR-1, bek or FGFR-2, FGFR-3 and FGFR-4)
and are known to be expressed in breast cancer cells [6].
Our experiments were performed with an antibody that rec-
ognized FGFR-1, but due to the structural similarities be-
tween FGFR family members, we cannot exclude other recep-
tor isotypes. FGFR activation by tyrosine phosphorylation
leads to the direct or indirect binding of SH2 domain-contain-
ing proteins which are crucial for mitogenic intracellular sig-
naling pathways [2]. A role for Src in FGF-2 mitogenic signal-
ing has been demonstrated [27] and members of the Src family
participate in the control of a variety of cellular functions,
including response to growth factors [28]. We have observed
a small but signi¢cant increase of Src tyrosine phosphoryla-
tion after FGF-2 stimulation (data not shown). However, Src
protein can be phosphorylated on tyrosine in an inactive as
well as active state [25], so the increase of tyrosine phosphor-
ylation that we observed after FGF-2 stimulation cannot be
linked to the activation of Src tyrosine kinase activity. Using
an in vitro kinase assay in the manner of LaVallee and co-
workers [21], we demonstrated that Src kinase activity is in-
deed induced in MCF-7 cells by FGF-2. In addition, the
pharmacological inhibition of Src that we report here using
herbimycin and PP2 indicates that the tyrosine kinase activity
of Src is required for the mitogenic stimulation by FGF-2 in
breast cancer cells. In contrast, pharmacological inhibition of
PI3 kinase activity by wortmannin caused only a slight de-
crease in the FGF-2 mitogenesis and had no e¡ect on the
phosphorylation of glycogen synthase kinase 3 (GSK3; data
not shown), which is known to be a direct target of this
enzyme [29]. Therefore PI3 kinase does not seem to play a
signi¢cant role in the FGF-2-induced proliferation of MCF-7
cells.
Downstream of the activated receptors, we observed the
tyrosine phosphorylation of FRS2 in response to FGF-2 stim-
ulation. FRS2, a membrane-anchored docking protein, has
been shown to play a major role in mediating the signal
from activated FGF receptors to the Ras/MAP kinase cas-
cade. Ong et al. (2000) have recently shown that the PTB
domain of FRS2 associates with the juxtamembrane region
of FGFR-1 [30]. Moreover, FRS2 tyrosine phosphorylation
seems to be essential for the FGF mitogenic signaling path-
way because inhibition of FRS2 reduces activation of MAP
kinase [31] and the lack of FRS2 tyrosine phosphorylation in
MCF-7 Ras is correlated with an inhibition of the prolifera-
tion induced by FGF-2 [20]. Interestingly, FRS2 is also a
substrate for the nerve growth factor (NGF) receptor
p140TrkA [32]. We have recently demonstrated that NGF is
also mitogenic for breast cancer cells through the tyrosine
kinase activity of p140TrkA and the activation of the MAP
kinase cascade [24]. This suggests that mitogenic stimulation
of both FGF-2 and NGF requires the activation of the Ras/
MAP kinase pathway in breast cancer cells. However, it
should be noted that, in contrast to FGF-2, herbimycin A
and PP2 do not exhibit any inhibiting activity for NGF-in-
duced mitogenesis, whereas wortmannin does (unpublished
data). These data con¢rm signi¢cant di¡erences in the FGF-
2 and NGF mitogenic signaling pathways despite their com-
mon requirement for the Ras/MAP kinase cascade.
The MAP kinase pathway is considered to be essential for
the activation of proliferation. The MAP kinases are known
to be overexpressed in human breast cancer cells and abnor-
malities in this signaling pathway play an important role in
growth deregulation of these cells [3]. We have shown that
FGF-2 mitogenic signaling does induce a transient activation
of the MAP kinase cascade. A transient activation of this
cascade is usually reported during mitogenic stimulation [3],
although it has also been shown that constitutive MAP kinase
activation (induced by Ras overexpression) can lead to an
inhibition of proliferation in MCF-7 cells [33]. In our experi-
ments, the requirement for activated MAP kinase is supported
by the complete inhibition of FGF-2-induced proliferation in
Fig. 6. A: Immunoblotting with anti-cyclin D2. MCF-7 cells were
stimulated by FGF-2 (10 ng/ml) for 10 min and cell lysates immu-
noprecipitated with anti-phosphotyrosine or anti-D2 antibodies.
After SDS^PAGE, immunoblotting was performed with anti-D2
antibodies using anti-goat antibodies as control. B: Tyrosine phos-
phorylation of cyclin D2. MCF-7 cells were exposed to FGF-2 (10
ng/ml) for 10 min with or without PD98059 (20 WM) or PP2 (50
nM). Cell lysates were immunoprecipitated with anti-D2 antibodies
and immunoblotting performed with anti-phosphotyrosine antibod-
ies.
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the presence of the MEK inhibitor, PD98059. Activation of
MAP kinase is necessary for the NGF-induced stimulation of
MCF-7 cell proliferation [24] whereas mitogenic stimulation
by insulin-like growth factor-1 (IGF-1) is independent of the
MAP kinase cascade and instead requires PI3 kinase activa-
tion [34]. These di¡erences between IGF-1 and FGF-2 signal-
ing indicate that the MAP kinase cascade is not always nec-
essary for the stimulation of proliferation and that the
signaling pathways used by IGF-1 and FGF-2 in breast can-
cer cells are clearly distinct.
The main consequence of the activation of MAP kinases is
their translocation into the nucleus and the activation of tran-
scription factors. This leads to changes in gene expression
which ultimately result in the stimulation of cell proliferation.
Progression through the cell cycle is under the strict control of
cyclins and their catalytic subunits, the Cdks (cyclin-depen-
dent kinases). In most cases, mitogenic factors act during
the G1 phase of the cell cycle, stimulating both the prolifer-
ation of quiescent cells arrested in G0 and the progression of
cycling cells through the restriction point in late G1 [35]. One
link between cell cycle progression and growth factor signal-
ing is provided by the D-type cyclins whose genes are induced
as a secondary response to mitogenic stimulation [36,37].
Although changes in cyclin D synthesis and activity have
been studied during cell cycle progression [38], modi¢cations
in the tyrosine phosphorylation of these proteins have not
been well described. Our data indicate that a major modi¢ca-
tion of tyrosine phosphorylation induced by FGF-2 involves a
30-kDa protein that we have identi¢ed as cyclin D2. The
phosphorylation of cyclin D1 on tyrosine has already been
described in osteosarcoma and lung epithelial cells [39], dem-
onstrating that cyclins can be recognized as substrates for ty-
rosine kinases. The tyrosine phosphorylation of cyclin D2 that
we have observed does not require MAP kinase activation as
it was not a¡ected by treatment with PD98059. In contrast,
Src protein is a candidate kinase for cyclin D2 phosphoryla-
tion. Indeed, Src has been shown to phosphorylate cyclin D1
in vitro [39] and, in our experiments, herbimycin A and PP2
decreased the tyrosine phosphorylation induced by FGF-2.
Further experiments are necessary to precisely de¢ne the sig-
naling pathway leading to cyclin D2 phosphorylation and the
function of this post-transcriptional modi¢cation.
In conclusion, our data lead to the following model. In
MCF-7 human breast cancer cells, the signaling pathway for
FGF-2 requires FGFR and FRS2 phosphorylation, as well as
Src and MAP kinase activation. In addition, FGF-2 mitogenic
stimulation induces the tyrosine phosphorylation of cyclin D2,
possibly through a mechanism involving Src. We therefore
hypothesize that cyclin D2 phosphorylation is an important
signaling event for the proliferation of breast cancer cells.
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